Consumer Health Study Aims to Evaluate the Safety, Tolerability and Impact of ED02 Probiotic Supplement on Gastrointestinal Outcomes

Part of paid clinical trials in Los Angeles, California.

Sponsor
Synbiotic Health
Study ID
NCT07423897
Status
Active Not Recruiting

Conditions

  • Gastrointestinal
  • Gut Health

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Bifidobacterium pseudocatenulatum — DIETARY_SUPPLEMENT
    Probiotic Supplement
  • Placebo — DIETARY_SUPPLEMENT
    Matching placebo

Study Details

The Study Team identified Bifidobacterium pseudocatenulatum ED02 as a safe and effective probiotic strain isolated from a healthy human donor. Research by the Study Team indicates that this strain lacks harmful genetic traits and can successfully mitigate infections from hypervirulent pathogens like Klebsiella pneumoniae without adverse effects.

Key Dates

Start date
Feb 2, 2026
Status verified
Mar 2026
Primary completion
Jun 17, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
35 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Placebo Comparator: Placebo Arm
    Matching Placebo
  • Active Comparator: Study Product Arm
    Participants taking the Probiotic Supplement

Primary Outcome Measure

Impact and Tolerability [ Time Frame: 4 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
People Science, Inc.Los AngelesCalifornia90045-

Find similar trials in Los Angeles, CA

By research site
People Science, Inc.· Los Angeles, CA

Related Studies